We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Biology of the SARS-CoV-2 mutations
- T cell response to vaccination
- The long-term health effects from a SARS-CoV-2 infection
- Current and future treatments for COVID-19
- Future work in the field
Biography
Paul Klenerman trained in medicine at Cambridge and Oxford and specialised in infectious diseases. He did his PhD in viral immunology at Oxford University and a postdoc in Zurich before returning to Oxford to establish a lab looking at immune responses to infection. The work includes studies of hepatitis C and a range of viruses affecting the lungs and liver - looking at how these evade the immune response, and the development of vaccines. He is focused especially on novel T cell responses in the mucosal surfaces which are critical for early host defence. He is an NIHR senior fellow and a Wellcome Trust investigator and holds a chair in the Nuffield Department of Medicine in Oxford.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Klenerman, P. (2021, March 22). The immune system response to the SARS-CoV-2 virus: March 2021 update [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 9, 2023, from https://hstalks.com/bs/4606/.Export Citation (RIS)
Publication History
Financial Disclosures
- There are no commercial/financial matters to disclose.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: Professor Klenerman, thank you for taking the time
today to do this newest update to what is
currently known in the immune system response to the SARS-CoV-2 virus.
What are some of the main changes which have
occurred since your last interview in December?
Prof. Klenerman: I think when we last talked
the spectre of the Kent variant was just emerging, and the vaccines were just licensed.
Since that time it's changed quite substantially, in terms of our understanding of
the significance of those variants and the deployment of the vaccines.
If I start with the variant,
when it first emerged it was clear there was a cluster in Kent of
a variant which was genetically distinct, and spreading apparently quite fast.
Indeed, as was predicted at the time,
it did spread substantially.
There was (of course), pre-Christmas,
an enormous amount of spread in the community anyway,
but the variant does appear to have some kind of advantage.
In terms of the biology and the immunology,
the impact of the individual mutations in the spike are a bit clearer now.
The virus is making mutations in that spike protein which do a couple of things.
One is to improve its ability to bind its receptor, which is ACE2.
In doing so, because that region of the spike is also a target for antibodies,
it can also evade a fraction of the antibody response.
It's not a very sharp peak so
that one mutation would knock out all the antibody responses, it's more of a surface.
That is evident when you look at
Hide